The long-term goal of the Prevention, Control, and Disparities (PCD) Program is to study how the research findings of basic, epidemiologic, and clinical research have been or should be disseminated and applied in real life. To achieve this end, the following Specific Goals will be pursued: 1) Primary prevention and early detection - We focus on the reduction of the use and ill effects of tobacco as well as other risk factors such as obesity, sedentary lifestyle, and diet and the study of screening for colorectal, cervical and other cancers; and 2) Health outcomes, quality of care and survivorship - We study patterns and quality of cancer care, and the impact of various factors on outcomes, including mortality and long-term side effects, and also study management and outcomes in cancer survivors. Thus, the Program's strengths in the study of primary prevention, as well as racial/ethnic disparities, survivorship and health outcomes research, have become significant and interactive with other programs in the Cancer Center, including the Breast Cancer Program, Cancer Epidemiology Program, Prostate Cancer Program, and others. The Program is also highly active within the local catchment area in research as well as providing service, and is developing a global research portfolio. The PCD Program consists of 34 members (24 full) from 16 departments among six schools within Columbia University. The Program is supported by large program project grants, including a Breast Cancer Center of Excellence grant to study racial disparities in breast cancer treatment, and multiple ROI s and other research grants. For the last full budget year of the grant (July 1, 2012 - June 30, 2013), the PCD Program received a total of $9.4M in cancer-relevant grant support, including $1.38M in NCI funding, $7.47M in other cancer-related peer-reviewed funding, and $0.55M in cancer-related non-peer-reviewed funding. The total number of publications since the previous submission (i.e., 2008-present) was 576 of which 16% were intra-programmatic and 40% inter-programmatic, and 10% were in high impact journals (Impact Factor >10).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-40
Application #
8753116
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2014-07-17
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
$33,319
Indirect Cost
$12,495
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Renz, Bernhard W; Takahashi, Ryota; Tanaka, Takayuki et al. (2018) ?2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell 33:75-90.e7
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793
Bakhoum, Mathieu F; Sengillo, Jesse D; Cui, Xuan et al. (2018) AUTOIMMUNE RETINOPATHY IN A PATIENT WITH A MISSENSE MUTATION IN PITPNM3. Retin Cases Brief Rep 12 Suppl 1:S72-S75

Showing the most recent 10 out of 331 publications